Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma
- PMID: 36317675
- DOI: 10.1002/pbc.30060
Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma
References
REFERENCES
-
- Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45(3):256-264.
-
- Büttgen K, Levy M. Juvenile xanthogranuloma (JXG). In: Corona R, ed. UpToDate ®. Wolters Kluwer; 2021.
-
- Rajendra B, Duncan A, Parslew R, Pizer BL. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer. 2009;52(3):413-415.
-
- Maintz L, Wenzel J, Irnich M, Reinhard H, Bieber T. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol. 2017;176(2):481-487.
-
- Histiocyte_Society, Histiocytosis NACf, Minkov M. NCT02205762: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis. Vol. 2022. U.S. National Library of Medicine: National Institutes of Health; 2014.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous